AK129 combination therapy for advanced solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an open-label, multicenter phase Ib/II trial designed to confirm the recommended Phase II dose (RP2D) and to evaluate safety and early signs of efficacy for AK129 given in combination with standard chemotherapies. The program uses dose-escalation cohorts followed by expansion cohorts in tumor-specific groups including NSCLC, HNSCC, and colorectal adenocarcinoma. Interventions include AK129 at two dose levels combined with agents such as pemetrexed, paclitaxel, or carboplatin depending on the cohort. Eligible patients are adults (18–75) with ECOG 0–1 and meet tumor- and prior-treatment–specific criteria, and primary endpoints focus on safety and dose with secondary endpoints addressing anti-tumor activity.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Be able and willing to provide written informed consent and to comply with all requirements of study participation (including all study procedures);
2. ≥18 years old and ≤ 75 years (regardless of sex);
3. ECOG performance status 0-1;
4. Life expectancy longer than 3 months;
5. 1)Histologically or cytologically confirmed diagnosis of Stage IIIB/C or IV NSCLC (American Joint Committee on Cancer \[AJCC\]); 2)No prior systemic anti-tumor therapy for locally advanced or metastatic NSCLC;must have received a platinum-based combination therapy and a PD-(L)1 monoclonal antibody for the treatment of locally advanced or metastatic disease and progressed during or after receiving prior therapy;
6. 1)Histologically or cytologically confirmed diagnosis of recurrent or metastatic HNSCC (American Joint Committee on Cancer \[AJCC\]); 2)No prior systemic anti-tumor therapy for recurrent or metastatic HNSCC ;must have received a platinum-based combination therapy and a PD-(L)1 monoclonal antibody for the treatment of recurrent or metastatic disease and progressed during or after receiving prior therapy;
7. Histologically or cytologically confirmed diagnosis of advanced colorectal adenocarcinoma with microsatellite stabilization;
8. Measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1;
9. Adequate organ function.

Exclusion Criteria:

1. Histologically or cytologically confirmed the presence of small cell carcinoma components/EGFR-sensitive mutations or ALK fusion positivite/known ROS1 rearrangement, MET exon 14 skipping mutation, EGFR exon 20 insertion mutation, BRAF V600E mutation, NTRK gene fusion positivite or RET gene fusion positivite;
2. Histologically or cytologically confirmed diagnosis of advanced colorectal adenocarcinoma with microsatellite highly unstable/mismatch repair gene expression defect (MSI-H/dMMR)or histopathological examination confirmed other pathological types;
3. Participating in another clinical research;
4. Has known active central nervous system (CNS) metastases, brain stem/meningeal metastasis, spinal cord metastasis or compression;
5. Has an active autoimmune disease that has required systemic treatment in the past 2 years;
6. Has known active tuberculosis (TB) and suspected active TB should be ruled out by clinical examination; known active syphilis infection; known active Hepatitis B or Hepatitis C;
7. Past or currently has non-infectious pneumonia/interstitial lung disease that requires systemic glucocorticoid therapy;
8. Has pleural effusion, pericardial effusion, or ascites that have clinical symptoms or require repeated drainage;
9. Had a history of myocarditis, cardiomyopathy, and malignant arrhythmia;
10. Has known allergy to any component of any investigational drug; a known history of severe hypersensitivity to other monoclonal antibodies;
11. Pregnant or lactating female.

Where it's running

• Liaoning Cancer Hospital
  Shenyang, Liaoning, China Recruiting

Study contacts

• Study coordinator: Wenting Li,M.D.
• Email: clinicaltrials@akesobio.com
• Phone: +86(0760)89873999

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CG-7321: a first-in-human test in advanced solid tumors

  We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.

  Recruiting at 4 sites Phase 1 Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · Fuzhou, Fujian and 3 other locations · NCT07923214

• AK157D1 injection for advanced solid tumors

  A first-in-human Phase 1 study tests AK157D1 injection in adults with unresectable advanced solid tumors to see if it is safe and tolerable and to get early signs of how it behaves in the body and against tumors.

  Recruiting Phase 1 Akeso · Harbin, Heilongjiang and 2 other locations · NCT07847281

• Triple-drug neoadjuvant therapy for EGFR-positive locally advanced head and neck cancer

  This trial tests a three-drug neoadjuvant regimen (Becotatug Vedotin, Pucotenlimab, and Cisplatin) in adults with EGFR-positive, locally advanced head and neck cancer to see if it can shrink tumors before surgery or chemoradiotherapy.

  Recruiting at 2 sites Phase 2 Sun Yat-sen University · Guangzhou, Guangdong and 1 other locations · NCT07814287

• BiP inhibitor BPR001-615 in colorectal adenocarcinoma

  This study tests whether the BiP inhibitor BPR001-615 can affect cancer cells from colorectal adenocarcinoma, in patients who will have surgical removal of their tumor at Nice University Hospital.

  Recruiting Centre Hospitalier Universitaire de Nice · Nice · NCT07813884

• VVD-133214 with Pembrolizumab in advanced colorectal cancer

  This study tests whether adding VVD-133214 to pembrolizumab helps people with advanced colorectal cancer better than pembrolizumab alone.

  Recruiting at 9 sites Phase 2 Vividion Therapeutics, Inc. · Tucson, Arizona and 121 other locations · NCT07811193

• ABBV-253 in adults with advanced solid tumors

  This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.

  Recruiting at 3 sites Phase 1 AbbVie · Grand Rapids, Michigan and 2 other locations · NCT07807956

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.